Six IL-6 blockers for SLE treatments and one IL-18 inhibitor for patients with NLRC4 and XIAP deficiency (monogenic IL-18 associated autoinflammatory conditions) are in phase II/III clinical trials (Table 1) [6, 198, 201–205]. Here, IL18 is linked to systemic lupus erythematosus.